OCTOBER 12, 2022

Nonalcoholic Steatohepatitis

Treatment Options for High-Risk Patients

Ashwani K. Singal, MD, MS, FACG, FAASLD, AGAF
Professor of Medicine, Department of Medicine
University of South Dakota Sanford School of Medicine
Transplant Hepatologist
Avera McKennan University Hospital
Chief of Clinical Research
Avera Transplant Institute
Sioux Falls, South Dakota

The management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) involves treatment of liver disease and its complications, control of risk factors, disease stabilization, and prevention